Advertisement

Virchows Archiv

, Volume 473, Issue 2, pp 189–197 | Cite as

Interobserver variability in the H&E-based assessment of tumor budding in pT3/4 colon cancer: does it affect the prognostic relevance?

  • Benedikt Martin
  • Eva Schäfer
  • Elzbieta Jakubowicz
  • Patrick Mayr
  • Regina Ihringer
  • Matthias Anthuber
  • Gerhard Schenkirsch
  • Tina Schaller
  • Bruno Märkl
Original Article

Abstract

Tumor budding is a mostly accepted adverse prognostic factor in colorectal carcinoma. It is on the cusp of a widespread use after agreement was reached recently on uniform assessment criteria. We investigated whether the interobserver variability has a direct influence on the prognostic relevance in pT3/4 colon cancer in the background of different levels of experience of the investigators. In total, six investigators with different levels of experience evaluated tumor budding on H&E slides in 244 cases with primary diagnosed (2002–2011) colon carcinoma (pT3/4, N+/−, M0). High-grade tumor budding/budding grade 3 (defined as majority assessment among the investigators) was significantly associated with an adverse outcome (overall survival p = 0.03, cancer-specific survival p = 0.08) and the occurrence of distant metastasis (p = 0.009). However, a detailed analysis of the rating results of the individual investigators revealed that only ratings of one investigator (advanced resident) were associated with an adverse outcome (p = 0.01 cancer-specific survival, overall survival p = 0.09, distant metastasis p = 0.002). The results of another investigator (consultant) were significantly associated with distant metastasis (p = 0.007). The kappa values among the investigators have a range between 0.077 and 0.357 (median 0.166). Total agreement of all investigators existed in 109 cases (44.7%). Our results demonstrate that the evaluation of tumor budding on H&E slides in pT3/4 colon cancer goes along with a considerable interobserver variability among investigators of different levels of experience. Furthermore, our results reveal that these findings directly influence the prognostic value.

Keywords

Colon cancer Tumor budding Interobserver variability Prognostic factor Histology 

Notes

Funding

The study was supported by the Hermann-Egger Foundation with 3000 Euro. The Hermann-Egger Foundation is a social foundation, which supports mainly regional projects (incl. science) in Augsburg.

Compliance with ethical standards

The Institutional Review Board of the Hospital Augsburg reviewed and approved the study protocol.

Conflict of interest

All authors declare that they have no conflict of interest.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65:87–108.  https://doi.org/10.3322/caac.21262 CrossRefPubMedGoogle Scholar
  2. 2.
    O’Connell JB, Maggard MA, Ko CY (2004) Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 96:1420–1425.  https://doi.org/10.1093/jnci/djh275 CrossRefPubMedGoogle Scholar
  3. 3.
    Hase K, Shatney C, Johnson D, Trollope M, Vierra M (1993) Prognostic value of tumor “budding” in patients with colorectal cancer. Dis Colon Rectum 36:627–635CrossRefPubMedGoogle Scholar
  4. 4.
    Shinto E, Jass JR, Tsuda H, Sato T, Ueno H, Hase K, Mochizuki H, Matsubara O (2006) Differential prognostic significance of morphologic invasive markers in colorectal cancer: tumor budding and cytoplasmic podia. Dis Colon Rectum 49:1422–1430.  https://doi.org/10.1007/s10350-006-0595-1 CrossRefPubMedGoogle Scholar
  5. 5.
    Koelzer VH, Assarzadegan N, Dawson H, Mitrovic B, Grin A, Messenger DE, Kirsch R, Riddell RH, Lugli A, Zlobec I (2017) Cytokeratin-based assessment of tumour budding in colorectal cancer: analysis in stage II patients and prospective diagnostic experience. J Pathol Clin Res 3:171–178.  https://doi.org/10.1002/cjp2.73 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Dawson H, Assarzadegan N, Riddell R, Kirsch R, Blank A, Zlobec I, Lugli A (2017) Tumor budding is a strong predictor of disease-free survival in stage II colorectal cancer: validation study based on the International Tumor Budding Consensus Conference (ITBCC) recommendations. J Clin Oncol 35:594–594.  https://doi.org/10.1200/JCO.2017.35.4_suppl.594 CrossRefGoogle Scholar
  7. 7.
    Märkl B, Arnholdt HM (2011) Prognostic significance of tumor budding in gastrointestinal tumors. Expert Rev Anticancer Ther 11:1521–1533.  https://doi.org/10.1586/era.11.156 CrossRefPubMedGoogle Scholar
  8. 8.
    Mitrovic B, Schaeffer DF, Riddell RH, Kirsch R (2012) Tumor budding in colorectal carcinoma: time to take notice. Mod Pathol Off J U S Can Acad Pathol Inc 25:1315–1325.  https://doi.org/10.1038/modpathol.2012.94 CrossRefGoogle Scholar
  9. 9.
    Rogers AC, Winter DC, Heeney A, Gibbons D, Lugli A, Puppa G, Sheahan K (2016) Systematic review and meta-analysis of the impact of tumour budding in colorectal cancer. Br J Cancer 115:831–840.  https://doi.org/10.1038/bjc.2016.274 CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, el Zimaity H, Fléjou JF, Hansen TP, Hartmann A, Kakar S, Langner C, Nagtegaal I, Puppa G, Riddell R, Ristimäki A, Sheahan K, Smyrk T, Sugihara K, Terris B, Ueno H, Vieth M, Zlobec I, Quirke P (2017) Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol Off J U S Can Acad Pathol Inc 30:1299–1311.  https://doi.org/10.1038/modpathol.2017.46 CrossRefGoogle Scholar
  11. 11.
    Kai K, Aishima S, Aoki S, Takase Y, Uchihashi K, Masuda M, Nishijima-Matsunobu A, Yamamoto M, Ide K, Nakayama A, Yamasaki M, Toda S (2016) Cytokeratin immunohistochemistry improves interobserver variability between unskilled pathologists in the evaluation of tumor budding in T1 colorectal cancer. Pathol Int 66:75–82.  https://doi.org/10.1111/pin.12374 CrossRefPubMedGoogle Scholar
  12. 12.
    Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I, Pecori S, Wang LM, Langner C, Mitomi H, Nakamura T, Watanabe M, Ueno H, Chasle J, Conley SA, Herlin P, Lauwers GY, Risio M (2012) Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology 61:562–575.  https://doi.org/10.1111/j.1365-2559.2012.04270.x CrossRefPubMedGoogle Scholar
  13. 13.
    Märkl B, Renk I, Oruzio DV et al (2010) Tumour budding, uPA and PAI-1 are associated with aggressive behaviour in colon cancer. J Surg Oncol 102:235–241.  https://doi.org/10.1002/jso.21611 CrossRefPubMedGoogle Scholar
  14. 14.
    Märkl B, Märkl M, Schaller T, Mayr P, Schenkirsch G, Kriening B, Anthuber M (2016) A new simple morphology-based risk score is prognostic in stage I/II colon cancers. Cancer Med 5:1492–1501.  https://doi.org/10.1002/cam4.737 CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159–174CrossRefPubMedGoogle Scholar
  16. 16.
    Märkl B, Hardt J, Franz S, Schaller T, Schenkirsch G, Kriening B, Hoffmann R, Rüth S (2017) Tumor budding, uPA, and PAI-1 in colorectal cancer: update of a prospective study. Gastroenterol Res Pract 2017:6504960–6504910.  https://doi.org/10.1155/2017/6504960 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, Lefor AT, Yasuda Y (2009) Evaluation of venous invasion by Elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol 33:1601–1607.  https://doi.org/10.1097/PAS.0b013e3181ae29d6 CrossRefPubMedGoogle Scholar
  18. 18.
    Ohtsuki K, Koyama F, Tamura T, Enomoto Y, Fujii H, Mukogawa T, Nakagawa T, Uchimoto K, Nakamura S, Nonomura A, Nakajima Y (2008) Prognostic value of immunohistochemical analysis of tumor budding in colorectal carcinoma. Anticancer Res 28:1831–1836PubMedGoogle Scholar
  19. 19.
    Choi H-J, Park K-J, Shin J-S, Roh MS, Kwon HC, Lee HS (2007) Tumor budding as a prognostic marker in stage-III rectal carcinoma. Int J Color Dis 22:863–868.  https://doi.org/10.1007/s00384-006-0249-8 CrossRefGoogle Scholar
  20. 20.
    Kanazawa H, Mitomi H, Nishiyama Y, Kishimoto I, Fukui N, Nakamura T, Watanabe M (2008) Tumour budding at invasive margins and outcome in colorectal cancer. Colorectal Dis Off J Assoc Coloproctology G B Irel 10:41–47.  https://doi.org/10.1111/j.1463-1318.2007.01240.x CrossRefGoogle Scholar
  21. 21.
    Ueno H, Murphy J, Jass JR, Mochizuki H, Talbot IC (2002) Tumour “budding” as an index to estimate the potential of aggressiveness in rectal cancer. Histopathology 40:127–132CrossRefPubMedGoogle Scholar
  22. 22.
    Ueno H, Price AB, Wilkinson KH, Jass JR, Mochizuki H, Talbot IC (2004) A new prognostic staging system for rectal cancer. Ann Surg 240:832–839CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Okuyama T, Nakamura T, Yamaguchi M (2003) Budding is useful to select high-risk patients in stage II well-differentiated or moderately differentiated colon adenocarcinoma. Dis Colon Rectum 46:1400–1406.  https://doi.org/10.1097/01.DCR.0000084413.78455.89 CrossRefPubMedGoogle Scholar
  24. 24.
    Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe M (2008) Tumor budding as an index to identify high-risk patients with stage II colon cancer. Dis Colon Rectum 51:568–572.  https://doi.org/10.1007/s10350-008-9192-9 CrossRefPubMedGoogle Scholar
  25. 25.
    Prall F, Nizze H, Barten M (2005) Tumour budding as prognostic factor in stage I/II colorectal carcinoma. Histopathology 47:17–24.  https://doi.org/10.1111/j.1365-2559.2005.02161.x CrossRefPubMedGoogle Scholar
  26. 26.
    Wang LM, Kevans D, Mulcahy H, OʼSullivan J, Fennelly D, Hyland J, OʼDonoghue D, Sheahan K (2009) Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol 33:134–141.  https://doi.org/10.1097/PAS.0b013e318184cd55 CrossRefPubMedGoogle Scholar
  27. 27.
    Cappellesso R, Luchini C, Veronese N, Lo Mele M, Rosa-Rizzotto E, Guido E, de Lazzari F, Pilati P, Farinati F, Realdon S, Solmi M, Fassan M, Rugge M (2017) Tumor budding as a risk factor for nodal metastasis in pT1 colorectal cancers: a meta-analysis. Hum Pathol 65:62–70.  https://doi.org/10.1016/j.humpath.2017.04.013 CrossRefPubMedGoogle Scholar
  28. 28.
    Graham RP, Vierkant RA, Tillmans LS, Wang AH, Laird PW, Weisenberger DJ, Lynch CF, French AJ, Slager SL, Raissian Y, Garcia JJ, Kerr SE, Lee HE, Thibodeau SN, Cerhan JR, Limburg PJ, Smyrk TC (2015) Tumor budding in colorectal carcinoma: confirmation of prognostic significance and histologic cutoff in a population-based cohort. Am J Surg Pathol 39:1340–1346.  https://doi.org/10.1097/PAS.0000000000000504 CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Sy J, Fung CL-S, Dent OF, Chapuis PH, Bokey L, Chan C (2010) Tumor budding and survival after potentially curative resection of node-positive colon cancer. Dis Colon Rectum 53:301–307.  https://doi.org/10.1007/DCR.0b013e3181c3ed05 CrossRefPubMedGoogle Scholar
  30. 30.
    Koelzer VH, Zlobec I, Berger MD, Cathomas G, Dawson H, Dirschmid K, Hädrich M, Inderbitzin D, Offner F, Puppa G, Seelentag W, Schnüriger B, Tornillo L, Lugli A (2015) Tumor budding in colorectal cancer revisited: results of a multicenter interobserver study. Virchows Arch Int J Pathol 466:485–493.  https://doi.org/10.1007/s00428-015-1740-9 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of PathologyKlinikum AugsburgAugsburgGermany
  2. 2.Department of Visceral SurgeryKlinikum AugsburgAugsburgGermany
  3. 3.Clinical and Population-Based Cancer Registry AugsburgAugsburgGermany

Personalised recommendations